2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

$2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study$

2026 SPS Puerto Rico | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

0% Complete

Course Content

Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma. A Review of Phase III IRAKLIA Study

This material is non-CME, no credits are available, and a certificate will not be provided upon completion.

Course Details

Duration: 0.00 hour
Released: Jun 22, 2026
Last Review: Jun 22, 2026
Expires: Jun 22, 2029

Target Audience

Pharmacists

Accreditation

NA

Related Courses

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

2026 SPS Puerto Rico | Specialty Pharmaceuticals: The Payer Perspective

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

2026 SPS Puerto Rico | Building Cell and Gene Therapy Program to Close Equity Gaps

Explore More Courses